Checkmate 649 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

San franciscoUnited statesYelenay janjigianFirst line treatmentAdvanced gastricGastroesophageal junctionEsophageal adenocarcinomaYear follow upPartnership withCancers symposiumGastric cancerGastrointestinal cancerAdvanced gastric cancerGastroesophageal junction cancerCheckmate 649Ge junction cancer